NO20092271L - Metoder og formuleringer for forbedret biotilgjengelighet av antiprogestiner - Google Patents

Metoder og formuleringer for forbedret biotilgjengelighet av antiprogestiner

Info

Publication number
NO20092271L
NO20092271L NO20092271A NO20092271A NO20092271L NO 20092271 L NO20092271 L NO 20092271L NO 20092271 A NO20092271 A NO 20092271A NO 20092271 A NO20092271 A NO 20092271A NO 20092271 L NO20092271 L NO 20092271L
Authority
NO
Norway
Prior art keywords
improved bioavailability
antiprogestins
formulations
methods
antiprogestin
Prior art date
Application number
NO20092271A
Other languages
English (en)
Inventor
Joseph Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of NO20092271L publication Critical patent/NO20092271L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Det tilveiebringes preparater omfattende et antiprogestin og som har forbedret biotilgjengelighet.I ett aspekt tilveiebringes det preparater omfattende partikler av et antiprogestin avsatt på et bærersubstrat. I et annet aspekt tilveiebringes det preparater omfattende et mikronisert antiprogestin. Det tilveiebringes også anvendelse av preparater omfattende et antiprogestin og som har forbedret biotilgjengelighet, for behandling av endometriose, uterme fibroider, dysmenorré og meningiomer.
NO20092271A 2006-12-28 2009-06-12 Metoder og formuleringer for forbedret biotilgjengelighet av antiprogestiner NO20092271L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88242306P 2006-12-28 2006-12-28
US88537207P 2007-01-17 2007-01-17
PCT/US2007/088891 WO2008083192A2 (en) 2006-12-28 2007-12-27 Methods and formulations for improved bioavailability of antiprogestins

Publications (1)

Publication Number Publication Date
NO20092271L true NO20092271L (no) 2009-08-06

Family

ID=39589194

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092271A NO20092271L (no) 2006-12-28 2009-06-12 Metoder og formuleringer for forbedret biotilgjengelighet av antiprogestiner

Country Status (14)

Country Link
EP (1) EP2094275A2 (no)
JP (1) JP2010514793A (no)
KR (1) KR20090086470A (no)
AR (1) AR064697A1 (no)
AU (1) AU2007339820A1 (no)
CA (1) CA2672888A1 (no)
CL (1) CL2007003855A1 (no)
CO (1) CO6190605A2 (no)
EA (1) EA200970646A1 (no)
EC (1) ECSP099536A (no)
MX (1) MX2009006912A (no)
NO (1) NO20092271L (no)
TW (1) TW200831110A (no)
WO (1) WO2008083192A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
BRPI1014035A2 (pt) 2009-04-14 2016-04-12 Hra Pharma Lab método para contracepção.
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
WO2013059664A1 (en) * 2011-10-21 2013-04-25 Seachaid Pharmaceuticals, Inc. Pharmaceutical compositions and uses thereof
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2999081B1 (fr) * 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone
SG11201507260QA (en) 2013-04-10 2015-10-29 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
US20200069702A1 (en) * 2016-12-09 2020-03-05 Repros Therapeutics Inc. Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
WO2023033900A1 (en) 2021-09-06 2023-03-09 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710139B2 (en) * 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2821555B1 (fr) * 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
AU2006294449A1 (en) * 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride

Also Published As

Publication number Publication date
KR20090086470A (ko) 2009-08-12
AR064697A1 (es) 2009-04-22
EP2094275A2 (en) 2009-09-02
CO6190605A2 (es) 2010-08-19
AU2007339820A1 (en) 2008-07-10
ECSP099536A (es) 2009-08-28
CL2007003855A1 (es) 2008-03-14
WO2008083192A2 (en) 2008-07-10
WO2008083192A3 (en) 2008-11-27
EA200970646A1 (ru) 2009-12-30
JP2010514793A (ja) 2010-05-06
MX2009006912A (es) 2009-08-12
TW200831110A (en) 2008-08-01
WO2008083192A8 (en) 2009-07-09
CA2672888A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
NO20092271L (no) Metoder og formuleringer for forbedret biotilgjengelighet av antiprogestiner
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
UA91027C2 (ru) ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53
NO20091706L (no) Inhibitorer av hepatitt C virus
WO2009016462A3 (en) Substituted bicyclolactam compounds
EA200900267A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ И СТЕРОИДОВ
MX336807B (es) Composiciones y metodos para producir una composicion.
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
MY148634A (en) Pyridazinone derivatives
SG162804A1 (en) Pyrazole based lxr modulators
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
TW200643453A (en) Polymerizable composition comprising low molecular weight organic component
EP2374812A3 (en) 4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication
MX2007012090A (es) Derivados sustituidos de pirazoliloxifenilo como herbicidas.
TNSN08174A1 (en) Novel 1-aza bicycloalkyl derivatives for the treatment of psychotic and neurodegenerative disorders
WO2006104945A3 (en) Hepatitis c therapies
MX2010003060A (es) Inhibidores de la interaccion entre mdm2 y p53.
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
CY1113409T1 (el) Αναστολεις ακτ και ρ70 s6 κινασης
UA97369C2 (ru) Противоопухолевые соединения дигидропиран-2-она и фармацевтическая композиция на их основе
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
EA200800393A1 (ru) Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application